Open AccessSotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Author(s) -
Deepak L. Bhatt,
Michael Szarek,
Bertram Pitt,
Christopher P. Can,
Lawrence A. Leiter,
Darren K. McGuire,
Julia B. Lewis,
Matthew C. Riddle,
Silvio E. Inzucchi,
Mikhail Kosiborod,
David Z.I. Cherney,
Jamie P. Dwyer,
Benjamin M. Scirica,
Clifford J. Bailey,
Rafael Díaz,
Kausik K. Ray,
Jacob A. Udell,
Renato D. Lópes,
Pablo Lapuerta,
Philippe Gabríel Steg
Publication year - 2020
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa2030186
Subject(s) - diabetes mellitus , medicine , kidney disease , disease , intensive care medicine , endocrinology
The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom